In the search for new anti-cancer agents, gemcitabine (2',2'-difluorodeoxycytidine, dFdC) has recently emerged from the preclinical drug development stage as a promising candidate for the treatment of non-haemotological malignancies. Gemcitabine is a new antimetabolite active against human leukaemic cell lines in vitro and a number of solid murine and human tumours in mice (Hertel et al., 1990; Braakhuis et al., 1991) . The preclinical activity of gemcitabine was more pronounced than that of the nucleoside analogue 1-0-Darabinofuranosylcytosine (ara-C), a drug commonly used in the treatment of adult acute leukaemia. Both drugs inhibit cellular proliferation in S phase and cause cells to accumulate in the G1-S phase (Hertel et al., 1990) . The apparent similarities in the molecular structures and the reversal of cytotoxicity by deoxycytidine led to comparative studies on the metabolic and pharmacokinetic characteristics of gemcitabine and ara-C (Heinemann et al., 1988) . It was found in Chinese hamster ovary cells, that the cellular concentration of the 5'-triphosphate of gemcitabine (dFdCTP) was 20-fold greater than that observed for ara-CTP at equimolar concentrations of the drugs. These differences in cellular accumulation of the respective triphosphates were due to an increased membrane transport, a higher deoxycytidine kinase affinity, and a longer retention of the intracellular 5'-triphosphate for gemcitabine relative to ara-C. The favourable characteristics of gemcitabine were the reason to introduce the drug into clinical trials Grunewald et al., 1992) .
The preclinical in vivo analysis of the anti-tumour efficacy of gemcitabine was first carried out in a variety of the well-known murine and human tumour systems (Hertel et al., 1990) . On the basis of a significant reduction in growth and cures in xenografts derived from squamous cell carcinoma tissue of the head and neck region, Braakhuis et al. (1991) suggested the drug of potential value in the treatment of head and neck cancer patients. In order to obtain further insight into the possible activity of gemcitabine against other malignancies, we extended the preclinical in vivo anti-tumour screening of gemcitabine in human tumour xenografts Table I have been described previously (Winograd et al., 1987; Boven et al., 1989; Molthoff et al., 1991) . Tumour lines were maintained by serial subcutaneous (s.c.) transplantation of tumour fragments of 2-3 mm in diameter in both flanks of 8-to 10-week-old animals.
Treatment and evaluation
Gemcitabine (Lilly Research Centre Limited) was provided as a powder and was dissolved in NaCl 0.9% to reach a final concentration of 10 mg ml -. In the first step of the experiment the drug was injected i.p. in various schedules to determine equitoxic doses. At these doses, the mice were required to lose between 5% and 15% of the initial weight within 2 weeks after the first injection. The equitoxic doses were assessed in non-tumour-bearing mice first and adjusted in tumour-bearing mice, if indicated. Thereafter, the efficacy of gemcitabine was determined in tumour-bearing mice with the use of three different doses and schedules. 
Results

Doses and schedules
The equitoxic doses of gemcitabine were based on the induction of a mean weight loss between 5% and 15% and were determined for daily x 5, every 3 days x 4, and weekly x 2 i.p. injections in non-tumour-bearing animals first. Starting doses were derived from previous experiments carried out by other investigators (Hertel et al., 1990; Braakhuis et al., 1991) . Doses of 10 mg kg-', 5 mg kg-', and 2.5 mg kg-l were administered for daily injections, but proved to be too toxic (mean weight loss > 20%) for doses of > 5 mg kg-'. In the treatment experiments animals were weighed only at the time of the injections or the weekly tumour measurements. Mean weight loss was calculated within 2 weeks after the first injection in non-lethal mice (Table II) . Except for toxic deaths, recovery from weight loss was rapid and invariably reversible within 1 week after treatment. Thus, mean weight loss for the weekly schedule depicted in Table II does not reflect the maximum weight loss to be expected, if (Table II) . In five of these, the every 3 days schedule was significantly more effective (P<0.001). With this schedule, 4/11 complete remissions could be obtained in A2780 xenografts. The anti-tumour effects reached with the weekly schedule were not significantly different from the extent of growth inhibition observed after the administration of 3.5 mg kg-' daily x 4. Again, the every 3 days schedule was significantly more effective than the daily schedule (P<0.001) in S.La(C), S.Hu and Ov.Pe xenografts. Days after initial treatment Figure 1 Treatment results of gemcitabine administered i.p. at the maximum tolerated dose of 240 mg kg-weekly x 2, 120 mg kg-' every 3 days x 4, or 3.5 mg kg-' daily x4 (----) 'lI-t visualises the superior efficacy of the every 3 days schedule compared to the weekly and the daily schedule in S.La(C), S.Hu and Ov.Pe xenografts.
Influence of dose Three human tumour lines with a variable degree of sensitivity to the weekly x 2 schedule of gemcitabine, S.La(C), S.Hu and Ov.Pe, were selected to study the presence of a possible relationship between the dose and the response to the drug. Tumour-bearing mice were treated for 6 weeks with weekly injections of 240 mg kg-', 120 mg kg-or 60 mg kgand another group of animals was treated with 2-weekly injections of 240 mg kg-'. In Figure 2 it is shown, that gemcitabine resulted in the reduction of tumour volume in S.La(C) xenografts, in stabilisation of tumour growth in Ov.Pe xenografts, while in S.Hu xenografts limited growth delay was obtained. The anti-tumour effects of the various doses expressed in percentages of growth inhibition (Table  III) were not greatly different. The 240 mg kg-' weekly x 6 schedule showed superior effects only in S.La(C) and S.Hu xenografts when compared to the same dose given every 2 weeks x 3, but the difference hardly reached the level of significance (P<0.05). However, in S.La(C) xenografts the number of complete remissions was highest for the 240 mg kg-x 6 schedule (9/10), followed by 120mg kg' x 6 and 60 mg kg-l x 6 (in both schedules 6/10) and the 240 mg kg-' 2-weekly x 3 schedule (4/8).
Discussion
For ara-C in the treatment of adult acute leukaemia patients it has been recognised, that drug efficacy is related to the schedule of administration, where a continuous infusion will induce a higher response rate than daily conventional doses over periods of 5-10 days (Freireich, 1987) . Gemcitabine also shows a schedule dependence. In our experiments we demonstrated, that the slightly more toxic daily schedule was less effective than the every 3 days schedule. A similar experience was reported by Hertel et al. (1990) in L1210 leukaemia. In addition we found, that the longer interval of 1 week between the injections will again result in a lower degree of growth inhibition. The clinical relevance of this finding is not yet known. In the various phase II trials presently underway a weekly schedule is being used consisting of treatment for 3 weeks followed by 1 week's rest (Lund et al., 1993) . Similar to the large differences in the administered doses per schedule in mice, patients can tolerate a considerably higher weekly dose of gemcitabine (the dose recommended for phase II trials is 1000mgm-2) than a daily dose of the drug (recommended dose 9 mg m-2), while in a 2-weekly schedule a dose of 4560 mg m-2 was well tolerated.
The low dose-response relationship for gemcitabine found in our human tumour lines may be explained by the cellular pharmacology of the drug. Phosphorylation by deoxycytidine kinase is required to induce cytotoxicity upon incorporation of dFdCTP into DNA. Inactivation of phosphorylated gemcitabine is caused by deamination to difluorouridine, a reaction catalysed by deoxycytidine deaminase (Heinemann et al., 1988; Gandhi & Plunkett, 1990) . In phase I clinical trials, Grunewald et al. (1990 Grunewald et al. ( , 1991 Grunewald et al. ( , 1992 have shown that the accumulation rate of dFdCTP in both leukaemia and mononuclear cells is saturated at certain plasma or intracellular drug levels. At higher gemcitabine doses, no further increase or even a decreased value of dFdCTP could be measured. Our experiments suggest, that the phosphorylation of gemcitabine in tumour cells is also a saturable process. Further pharmacodynamic analysis of the intracellular metabolism of gemcitabine will clarify the precise mechanism of action and the variation in cytotoxicity between tumour cells. If a relationship exists between the ability to accumulate and retain dFdCTP and the response, as has been demonstrated for high-dose continuous infusion of ara-C (Estey et al., 1990) , it is anticipated that in S.La(C) xenografts a higher area under the concentration-times-time curve (AUC) for dFdCTP can be reached when compared to S.Hu xenografts. In patients, the AUC of dFdCTP in mononuclear cells indeed augmented with prolonged administration of gemcitabine at a dose maintaining maximal dFdCTP accumulation . In tumour cells exposed to gemcitabine in vitro, dFdCTP accumulation was clearly demonstrated to be time dependent (Ruiz van Haperen et al., 1991) . Whether longer infusion periods will result in higher anti-tumour efficacy rather than increased side-effects in patients has yet to be determined.
In our laboratory we have found a good correlation between clinical data from phase II trials and the chemosensitivity of the panels of human soft tissue sarcoma xenografts and human ovarian cancer xenografts, both for conventional cytostatic agents and their analogues (Boven et al., 1985; Winograd et al., 1987; Boven, 1988; Boven et al., 1989; Boven et al., 1990; Boven, 1991) . The validity of the xenograft model has not yet been proven for all classes of antitumour agents, such as antimetabolites. On one hand, pharmacological differences between mouse and man may specifically be responsible for a negative correlation. As examples, mice can tolerate much lower doses of methotrexate and 5-fluorouracil relative to maximum doses in patients, which may be the reason that these drugs have low or no efficacy in head and neck cancer xenografts (Braakhuis et al., 1983) and colon cancer xenografts (Mattern et al., 1988) , respectively. On the other hand, a higher proportion of rapidly proliferating tumour cells in the log-phase of growth in xenografts as compared to patients' tumours may theoretically result in an increased susceptibility to the cytotoxicity of other antimetabolites, as may be the case for gemcitabine. However it appears, that the xenograft model can indeed predict clinical activity of gemcitabine in particular solid tumour types. Objective responses have been noted in a variety of malignancies, including non-small cell lung cancer, ovarian cancer and breast cancer patients (Lund et al., 1993) .
In conclusion, gemcitabine is a new nucleoside analogue with a unique mechanism of action, which should be investigated further for a rational design of clinical trials. Preclinical analysis of the anti-tumour activity against human tumour xenografts suggests, that the drug may be effective in soft tissue sarcoma and ovarian cancer patients.
